Compare ESCA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | VYGR |
|---|---|---|
| Founded | 1922 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.4M | 232.4M |
| IPO Year | N/A | 2015 |
| Metric | ESCA | VYGR |
|---|---|---|
| Price | $13.24 | $4.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 25.8K | ★ 469.2K |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | ★ 4.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $241,540,000.00 | $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.00 | $71.78 |
| P/E Ratio | $14.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.41 | $2.65 |
| 52 Week High | $16.99 | $6.55 |
| Indicator | ESCA | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 58.29 | 54.46 |
| Support Level | $12.53 | $3.74 |
| Resistance Level | $13.09 | $4.51 |
| Average True Range (ATR) | 0.37 | 0.21 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 77.23 | 84.94 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.